$853 Million is the total value of Bain Capital Life Sciences Investors, LLC's 35 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 14.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | SPRINGWORKS THERAPEUTICS INC | $118,947,000 | -56.4% | 4,831,307 | 0.0% | 13.95% | -47.3% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $105,945,000 | +16.1% | 8,415,000 | 0.0% | 12.42% | +40.3% | |
| PHVS | PHARVARIS N V | $70,291,000 | +21.9% | 3,180,601 | 0.0% | 8.24% | +47.1% | |
| ARQT | Sell | ARCUTIS BIOTHERAPEUTICS INC | $63,930,000 | -16.6% | 3,000,000 | -24.6% | 7.50% | +0.7% |
| EQRX INC | $46,917,000 | +13.6% | 10,003,573 | 0.0% | 5.50% | +37.1% | ||
| NUVALENT INC | $46,484,000 | -2.4% | 3,428,014 | 0.0% | 5.45% | +17.9% | ||
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $42,999,000 | -3.5% | 2,305,558 | +13.6% | 5.04% | +16.5% |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $40,026,000 | +53.8% | 8,663,673 | +32.8% | 4.69% | +85.8% |
| Sell | AMYLYX PHARMACEUTICALS INC | $37,523,000 | +6.0% | 1,948,214 | -29.3% | 4.40% | +27.9% | |
| RAPID MICRO BIOSYSTEMS INC | $36,269,000 | -36.7% | 8,434,560 | 0.0% | 4.25% | -23.5% | ||
| CARA | New | CARA THERAPEUTICS INC | $24,171,000 | – | 2,647,473 | +100.0% | 2.84% | – |
| NRIX | Buy | NURIX THERAPEUTICS INC | $23,096,000 | +28.4% | 1,822,883 | +41.9% | 2.71% | +55.0% |
| 2SEVENTY BIO INC | $18,597,000 | -22.6% | 1,408,901 | 0.0% | 2.18% | -6.6% | ||
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $17,881,000 | – | 2,260,572 | +100.0% | 2.10% | – |
| SVRA | SAVARA INC | $17,666,000 | +16.0% | 11,622,598 | 0.0% | 2.07% | +40.1% | |
| AVIR | ATEA PHARMACEUTICALS INC | $17,648,000 | -1.7% | 2,485,638 | 0.0% | 2.07% | +18.8% | |
| CCCC | C4 THERAPEUTICS INC | $12,382,000 | -68.9% | 1,642,210 | 0.0% | 1.45% | -62.5% | |
| ANNX | ANNEXON INC | $12,221,000 | +38.1% | 3,241,628 | 0.0% | 1.43% | +66.6% | |
| RACB | RESEARCH ALLIANCE CORP II | $9,800,000 | +0.4% | 1,000,000 | 0.0% | 1.15% | +21.2% | |
| TANGO THERAPEUTICS INC | $8,706,000 | -40.2% | 1,921,790 | 0.0% | 1.02% | -27.8% | ||
| ACAD | New | ACADIA PHARMACEUTICALS INC | $8,461,000 | – | 600,523 | +100.0% | 0.99% | – |
| XILIO THERAPEUTICS INC | $8,192,000 | -58.7% | 2,805,413 | 0.0% | 0.96% | -50.1% | ||
| MARINUS PHARMACEUTICALS INC | $6,926,000 | -48.2% | 1,431,058 | 0.0% | 0.81% | -37.5% | ||
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $6,867,000 | +0.1% | 700,000 | 0.0% | 0.80% | +20.9% | |
| ADAGIO THERAPEUTICS INC | $6,354,000 | -28.1% | 1,937,207 | 0.0% | 0.74% | -13.2% | ||
| SYRS | SYROS PHARMACEUTICALS INC | $6,031,000 | -19.1% | 6,264,420 | 0.0% | 0.71% | -2.3% | |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $5,380,000 | -38.0% | 2,000,000 | 0.0% | 0.63% | -25.1% | |
| APTX | APTINYX INC | $4,961,000 | -75.4% | 8,891,758 | 0.0% | 0.58% | -70.3% | |
| SLDB | SOLID BIOSCIENCES INC | $4,882,000 | -48.7% | 7,929,918 | 0.0% | 0.57% | -38.0% | |
| PANA | PANACEA ACQUISITION CORP II | $4,880,000 | +0.1% | 500,000 | 0.0% | 0.57% | +20.9% | |
| ARYA SCIENCES ACQUISITN CORP | $4,860,000 | +0.1% | 500,000 | 0.0% | 0.57% | +20.8% | ||
| BLSA | BCLS ACQUISITION CORP | $4,826,000 | +0.3% | 487,500 | 0.0% | 0.57% | +21.2% | |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $2,961,000 | -1.2% | 300,000 | 0.0% | 0.35% | +19.2% | |
| XFOR | X4 PHARMACEUTICALS INC | $2,914,000 | -44.9% | 3,019,540 | 0.0% | 0.34% | -33.3% | |
| AGLE | Buy | AEGLEA BIOTHERAPEUTICS INC | $2,701,000 | -58.8% | 5,347,689 | +87.8% | 0.32% | -50.2% |
| JYAC | Exit | JIYA ACQUISITION CORP | $0 | – | -300,000 | -100.0% | -0.29% | – |
| OMEG | Exit | OMEGA ALPHA SPACcl a | $0 | – | -400,000 | -100.0% | -0.38% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
- BCIP Life Sciences Associates, LP #6
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.